trial
as of 2026-07-01Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
NCTId NCT00254202
at a glance
Phase 3 · Completed
Enrollment 593 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2006-09-26
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
593 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-11-18
Primary completion
2006-09-26
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
42 total
Little Rock, United StatesAnaheim, United StatesCerritos, United StatesGarden Grove, United StatesGlendale, United StatesLos Angeles, United StatesNational City, United StatesOceanside, United StatesParamount, United StatesPico Rivera, United StatesSan Diego, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
593
Phase
PHASE3
Primary Completion Date
2006-09-26
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication